Repro Med Systems Inc (REPR)

[blue_skies]

the stock does look like it is under pressure. Some of that is attributed to a wide spread between the bid and the ask.And the stock has had quite a run over the last year! Churning and back filling is normal for the stock to continue a healthy rate of appreciation. Wild gyrations of some small company stock prices is symptomatic of unreal exceptions with money rushing into and out of a stock.That kind of stock movement is speculation. REPR is a small speculative stock with a good management team and a good story.

As to the Q3 earnings:
I see the company beginning to hit its stride. The company has put in place a good management team and has a diversified independence board of directors to lean on for additional guidance. The new chairman of the board, John Fletcher is highly qualified!!! See link below.

Two of the three lawsuits against the company have been settled favorably. There is no reason to believe the remaining one will have a different outcome. There will be a large reduction of legal expenses which will be more apparent in the fourth quarter.

Four months ago the FDA approved the subq formulation of Xembify. RMS is partnering with the drug maker and a few early sales might show this quarter.More sales will come in Q4 and excel through 2020.

About 6 months ago the FDA approved the super26 needle set. I expect a marketing launch of this needle set to be happening momentarily. (With a white paper??) Lets see what is said at CC.

The resent uplisting with the rebranding is the next chapter in what has been a successful story over the last year or so. As a NADAQ listed stock more and bigger investors can invest in the stock. More analyst will begin to follow the stock

So as to the Q3 earnings, I see a company executing. It does what it says it will do so I am comfortable holding the stock at this price.


https://www.marketwatch.com/press-release/rms-medical-products-names-r-john-fletcher-chairman-of-the-board-2019-09-30?mod=mw_quote_news